Literature DB >> 1909702

High levels of serum soluble interleukin-2 receptors in hyperthyroid patients: correlation with serum thyroid hormones and independence from the etiology of the hyperthyroidism.

E Koukkou1, P Panayiotidis, V Alevizou-Terzaki, N Thalassinos.   

Abstract

The serum levels of soluble interleukin-2 receptors (s-IL-2R) and soluble CD8 antigens (s-CD8) were measured in 33 patients with Graves' disease (GD), 29 with toxic nodular goiter (TNG), 6 with toxic adenoma (TA), and 12 with hypothyroidism, as well as in 11 patients with infectious mononucleosis (known to have high s-IL-2R and s-CD8 levels) and 34 normal controls. Serum levels of T3 and T4, both total and free, and of TSH were simultaneously determined. s-IL-2R levels were significantly higher in all patients with hyperthyroidism (mean +/- SD, 3276 +/- 1273 U/mL for GD, 4183 +/- 1832 for TNG, and 1671 +/- 648 for TA) compared to normal control values (P less than 0.001 for GD and TNG and P less than 0.01 for TA), while in the euthyroid state they were within the normal range (535 +/- 240 U/mL). Hypothyroid patients had significantly lower s-IL-2R levels compared to normal controls (P less than 0.05). A positive correlation (P less than 0.001) between serum s-IL-2R levels and total/free T3-T4 levels was found in these groups of patients, while no correlation between s-CD8 levels and s-IL-2R/T3/T4 was found. These findings suggest an association between hyperthyroxinaemia and activation of human lymphocytes in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1909702     DOI: 10.1210/jcem-73-4-771

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Serum levels of interleukin-12 in Graves' disease and their dynamic changes after surgery.

Authors:  Saburo Murakami; Katsuhiko Okubo; Yoshitaka Tsuji; Hideto Sakata; Masataka Kikuchi; Takehiro Takahashi; Takaharu Kato; Renzo Hirayama
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

2.  Serum-soluble interleukin-2 receptor levels before and after surgical treatment for Graves' disease.

Authors:  S Murakami; A Kobayashi; K Kuma; H Murai; Y Okamura; A Satomi; K Ishida
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

3.  Soluble interleukin-2 receptor is a thyroid hormone-dependent early-response marker in the treatment of thyrotoxicosis.

Authors:  R C Smallridge; G C Tsokos; K D Burman; L Porter; T Cranston; P P Sfikakis; B L Solomon
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

4.  Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy.

Authors:  M F Prummel; W M Wiersinga; R Van der Gaag; M P Mourits; L Koornneef
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

5.  Serum soluble interleukin-2 receptors as an index of the biological activity of thyroid hormones in hyperthyroidism.

Authors:  E Koukkou; P Panayiotidis; N Thalassinos
Journal:  J Endocrinol Invest       Date:  1995-04       Impact factor: 4.256

6.  Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma.

Authors:  S Mariotti; G Barbesino; P Caturegli; M Marinò; L Manetti; L Fugazzola; F Pacini; A Pinchera
Journal:  J Endocrinol Invest       Date:  1994-12       Impact factor: 4.256

7.  A case of thyrotoxicosis-induced anemia in a patient with painless thyroiditis.

Authors:  Ichiro Komiya; Takeaki Tomoyose; Noriharu Yagi; Gen Ouchi; Tamio Wakugami
Journal:  Thyroid Res       Date:  2021-04-23

8.  Provirus load in patients with human T-cell leukemia virus type 1 uveitis correlates with precedent Graves' disease and disease activities.

Authors:  A Ono; E Ikeda; M Mochizuki; M Matsuoka; K Yamaguchi; T Sawada; S Yamane; S Tokudome; T Watanabe
Journal:  Jpn J Cancer Res       Date:  1998-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.